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OBJECTIVE — To determine whether pharmacological treatment of depression in low-
income minorities with diabetes improves A1C and quality of life (QOL).
RESEARCH DESIGN AND METHODS — This was a 6-month, randomized, double-
blind, placebo-controlled trial. Patients were screened for depression using Whooley’s two-
question tool at a county diabetes clinic. Depression was conﬁrmed (or not) with the
Computerized Diagnostic Interview Survey (CDIS) software program, and the severity of de-
pression was assessed monthly by the Hamilton Depression Scale (HAM-D). Depressed subjects
with A1C levels 8.0% were randomly assigned to receive either sertraline or placebo. Diabetes
care was provided by nurses following detailed treatment algorithms who were unaware of
therapy for depression.
RESULTS — Atotalof150subjectsansweredpositivelytoatleastonequestiononWhooley’s
questionnaire. The positive predictive value for depression diagnosed by CDIS was 69, 67, and
84% for positive answers to question 1 only, question 2 only, or both, respectively. Of the 89
subjectswhoenteredthestudy,75completed.Anintention-to-treatanalysisrevealedsigniﬁcant
differences between baseline and 6 months in HAM-D and pain scores, QOL, and A1C and
systolic blood pressure levels in both groups, with no differences between groups for the ﬁrst
threebutasigniﬁcantlygreaterdecreasewithsertralineinA1Candsystolicbloodpressurelevels.
Changes in HAM-D scores and A1C levels were signiﬁcantly correlated in all subjects (P  0.45
[P  10
6]).
CONCLUSIONS — In this low-income minority population, pharmacological treatment of
depression signiﬁcantly improved A1C and systolic blood pressure levels compared with
placebo.
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T
he prevalence of depression among
people with diabetes is more than
twice that of the general population
(1). Coexistence of depression in persons
withdiabetesisassociatedwithworsegly-
cemic control (2), which may be due to
less adherence to self-care behaviors and
medications (3). Eventually, there is in-
creased morbidity (4) and mortality (5)
and higher medical costs (6).
The prevalence of untreated depres-
sion in people with diabetes is higher in
minorities (1). Yet, screening for and
treating depression are less common in
this population (7). Very little research
has been published on diabetes and de-
pression with a focus on minority popu-
lations,whohavesigniﬁcantdisparitiesin
outcomes (8), such as higher A1C levels
(9),increasedratesofcomplications(10),
and more severe depression (8).
Depression is associated with worse
glycemic control (2). Some studies have
evaluated whether treatment of depres-
sion will improve A1C levels (11–20).
However, these drug studies were open
label, were of short duration, and/or were
conducted in highly educated (more than
high school education) Caucasian popu-
lations. Most showed that although de-
pression was improved, A1C levels were
not. We sought to determine whether use
of antidepressants in a minority popula-
tionwithuncontrolleddiabetesimproved
their A1C levels, quality of life (QOL),
and depression compared with placebo.
RESEARCH DESIGN AND
METHODS— This was a 6-month
randomized, double-blind, placebo-
controlledstudy.PatientsinaLosAngeles
County diabetes clinic were screened for
depression with Whooley’s two-question
tool (21) (question 1: “During the past
month, have you often been bothered by
feeling down, depressed or hopeless?”;
question 2: “During the past month, have
you often been bothered by having little
interestorpleasureindoingthings?”).Pa-
tientswithpositiveanswerstooneorboth
of these questions who stated an interest
in participating in a study of depression
and diabetes had depression conﬁrmed
(or not) with the Computerized Diagnos-
tic Interview Survey (CDIS) software pro-
gram. If results were positive, the severity
of depression was assessed by the Hamil-
ton Depression (HAM-D) survey, a 21-
question survey that is the most widely
used outcome measure for evaluating de-
pression severity (22). Exclusion criteria
were current use of antidepressants, A1C
levels8%,pregnancy,dialysis,liverdis-
ease by history or liver enzyme levels ele-
vated three times greater than normal,
blood pressure 160 mmHg systolic or
95 mmHg diastolic, a history of severe
depression (as determined by previous
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a positive answer to the suicide question
on the HAM-D survey on the initial
evaluation.
Once depression was positively diag-
nosed, subjects were randomly assigned
by a computer program to receive either
sertraline or placebo. The subject, study
coordinator, and investigator were un-
aware of the study group to which a given
patient was assigned. Study subjects con-
tinued their diabetes care in the county
diabetes clinic where it was provided by
nurses following detailed treatment algo-
rithms (23) who were unaware of the
therapy for depression. Study visits were
conducted monthly, at which time the
study coordinator evaluated the patient
usingtheHAM-Dscore.Bloodwasdrawn
for measurement of sertraline levels, pill
counts were done before new medication
was issued, and pain was assessed using a
visual numeric analog scale from 1 to 10
at each visit. At each study visit, the coor-
dinator discussed the laboratory results
and encouraged subjects to take both
their diabetes and study medications as
ordered.Sertralinewasstartedatadoseof
50 mg (one pill), and, if at the monthly
follow-up subjects’ depression scores on
the HAM-D questionnaire did not im-
prove (i.e., their scores did not decrease),
their medication was increased to two
pills, either placebo or 100 mg of sertra-
line. If a subject’s answer to the suicide
question on the HAM-D questionnaire
was positive, the psychiatry urgent care
clinic was paged and study personnel
took the subject to the mental health ur-
gentcarecenterlocatedoneﬂoorbelowin
the same building.
A1C levels were measured every 2
months. QOL was assessed at baseline
and at the end of the study by the
Diabetes-39 questionnaire (24). All sub-
jectswereseeningroupsessionsmonthly
for an American Diabetes Association–
approved diabetes education program
given by the study coordinator, in which
adherence to medications was also
stressed. At the last visit, subjects met
with the study psychiatrist who un-
blinded them and determined what fur-
ther depression treatment the subject
might need.
The primary outcome variable was
thechangeinA1Clevelsbetweenbaseline
and 6 months. The major secondary out-
comevariablewasthechangeinQOLat6
months compared with baseline. The
other secondary outcomes were the other
two outcome measures of diabetes, i.e.,
LDL cholesterol and blood pressure lev-
els,theloweringofwhichiscausallyrelated
to decreased diabetes complications, espe-
cially macrovascular disease. The data
were subjected to a test for normality
basedontheskewnessandkurtosisofthe
underlying frequency distribution. If re-
sults of this test were signiﬁcant, a non-
parametrictestwasthenusedonthedata.
An ANCOVA model or its nonparametric
equivalent (Wilcoxon’s rank-sum test
based on the differences from baseline)
wasusedtoassessdifferencesbetweenthe
two arms at 6 months; the two-tailed Stu-
dent’s t test or its nonparametric equiva-
lent (Wilcoxon’s rank-sum test) was used
to assess pairwise between-group differ-
ences. In addition, the within-group
change from baseline to 6 months was as-
sessed using Wilcoxon’s signed-rank test.
Secondary clinical outcomes also in-
cluded depression and pain scores. The
results were reported based on an intent-
to-treat analysis (last observation carried
forward)forbothdepressionanddiabetes
outcomes. To compare baseline charac-
teristics of study subjects, the 
2 test was
used for qualitative data and either the
two-sampletorWilcoxon’srank-sumtest
was used for quantitative end points.
The study was approved by the
Charles Drew University Institutional Re-
view Board. Subjects signed an informed
consent form before the CDIS evaluation.
RESULTS— For the study, 150 sub-
jects answered yes to at least one of the
two questions on Whooley’s question-
naire, and all subjects provided informed
consent for further evaluation. Of these,
123 tested positive for depression on the
CDIS for an overall positive predictive
value (PPV) for Whooley’s questionnaire
of 82%. The PPVs for positivity to ques-
tion 1 only, to question 2 only, or to both
were 69, 67, and 84%, respectively. Of
the 123 subjects who tested positive for
depression with the CDIS, 12 decided
against taking antidepressants, 21 had re-
peat A1C levels 8%, and 1 could not
make the frequent visits. Therefore, 89
subjects whose baseline characteristics
aresummarizedinTable1wererandomly
assigned; of these, 75 completed the
study. There were no signiﬁcant differ-
ences in baseline characteristics between
thetwogroups.Fourteensubjects(whose
baseline characteristics were similar to
those of the 75 completers) were with-
drawn from the study for the reasons
listed in Fig. 1.
Theresponsetotreatmentisshownin
Table 2. A1C levels fell signiﬁcantly in
both groups, but the decrease in the ser-
tralinegroupwasmorethantwiceasgreat
as that in the placebo group (2.0% 
2.1 vs. 0.9%  2.0, P  0.003). Mea-
surement of blood sertraline levels re-
vealedthat15ofthe45subjectswhowere
assigned to take the drug were not taking
it. However, the results were not changed
appreciably when these noncompliant
subjectswereomittedfromtheanalysisof
the sertraline group. Systolic blood pres-
sure fell signiﬁcantly in both groups, and
again the fall in the sertraline group was
signiﬁcantly greater than that in the pla-
cebo group (15  18 vs. 6  15
Table 1—Baseline demographics
Sertraline group Placebo group
n 45 44
Women 33 32
Age (years) 52  85 3  10
Hispanic 39 39
African American 5 5
Other 1
Years of diabetes 13  71 2  7
Type 2/type 1 diabetes 45/0 42/2
Pain scale 6  26  3
HAM-D* 19  52 0  6
A1C (%) 10.0  1.8 9.7  1.6
LDL cholesterol (mg/dl) 101  29 99  34
Systolic blood pressure (mmHg) 137  13 137  14
Diastolic blood pressure (mmHg) 73  97 5  12
Weight (lbs) 181.6  40.0 188.1  61.7†
Data are means  SD or n. *21-question survey to evaluate degree of depression. †n  43 (one patient in
wheelchair and weight not measured).
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signiﬁcantly in both groups with no dif-
ference between the groups. There was a
signiﬁcant (P  10
6) correlation of 0.45
between the changes in A1C levels and
HAM-D scores in the entire group of sub-
jects. There were signiﬁcant differences
betweenbaselineandendofstudyinboth
groups but no differences between the
two groups for pain scores (Table 2) and
QOL (Table 3). Diastolic blood pressure,
LDL cholesterol concentrations, and
weight did not change signiﬁcantly in ei-
thergroup.Theresultsweresimilarwhen
only the completers were analyzed.
CONCLUSIONS — Sertraline-treated
patients had greater improvement in A1C
and systolic blood pressure levels than
control patients, despite equivalent im-
provement in depression as measured by
HAM-D. Thus, depression and pain scores
(Table 2) and QOL (Table 3) improved sig-
niﬁcantly in patients receiving either sertra-
line or placebo, but there were no
differencesbetweenthetwogroups.Incon-
trast, although A1C levels fell signiﬁcantly
in both groups, the decrease in patients re-
ceiving sertraline was more than twofold
greater than in those receiving the placebo,
andthisdifferencebetweengroupswassta-
tistically signiﬁcant. However, there was a
very signiﬁcant (P  10
6) correlation of
0.45 between changes in depression and
A1C levels in all of the subjects. A placebo
effect to explain the signiﬁcant fall in the
control group would not be unexpected in
this situation and may have been enhanced
by the twice a month interaction with the
study coordinator. The interaction with
the study coordinator might also explain
the similar improvements in depression,
QOL, and pain scores between the two
groups. These questionnaires were ad-
ministered by the coordinator who often
had to provide verbal explanations to the
Figure 1—CONSORT diagram depicting subject ﬂow.
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did not want to “disappoint” her.
Theserobustpositiveeffectsofsertra-
line to signiﬁcantly lower A1C levels in
this study stand in contrast with most of
the literature concerning treatment of de-
pression in people with diabetes. In all of
the randomized trials (11–16,18,20), de-
pression scores signiﬁcantly improved.
However, pharmacological treatment
alone (11,13) or psychological plus phar-
macological treatment (15) did not affect
A1C levels. In one study (16), patients
were ﬁrst treated in an open-label fashion
with an antidepressant, and the 43% who
responded were randomly assigned to
continue either pharmacological treat-
ment or to receive a placebo in a mainte-
nance phase. Although recurrence of
depression was signiﬁcantly delayed by
the active drug, the improvement in A1C
levels during the open-label phase was
maintained with no difference between
the two groups during the maintenance
phase. In a mildly depressed group of di-
abetic patients, A1C levels signiﬁcantly
decreased at 3 months, but there was no
difference at 6 months between pharma-
cological and placebo treatment (18). In a
study evaluating cognitive behavior ther-
apy, A1C levels were similar to those in a
control group receiving no speciﬁc anti-
depressant therapy at the end of the 12-
week treatment period but were
signiﬁcantly lower 6 months later (12).
However, these levels remained high in
both groups (9.5% vs. 10.9%). Finally, in
a randomized clinical trial in which de-
pressed patients received a combination
of pharmacological and psychological
treatments compared with usual care,
there was no difference in A1C levels
when the entire groups were analyzed
(15). However, in the active treatment
group, A1C levels fell signiﬁcantly in
those who had high depression scores
compared with those with low scores.
Thisdifferencewasnotfoundintheusual
care group.
Conﬂicting results were seen in two
open-label studies. In one, in which de-
pression was treated with an antidepres-
sant, A1C levels were signiﬁcantly
decreased in those whose depression im-
provedbutnotinthosewhodidnotshow
a remission (17). In the other one in
which treatment was by group cognitive
behavior therapy, depression signiﬁ-
cantly improved but there was no change
in A1C levels (20).
The PPVs for yes answers to question
1 only, to question 2 only, or to both on
Whooley’s questionnaire were 69, 67,
and 84%, respectively. To the best of our
knowledge,thisistheﬁrststudytoevaluate
the PPVs of the responses to Whooley’s
questionnaire using an objective measure
for the diagnosis of depression, the CDIS.
These results suggest that this simple
two-questionscreeningtoolcouldbean
Table 2—Response to treatment
Sertraline Placebo P
A1C levels (%)
Baseline 10.0  1.8 9.7  1.6 NS
6 months 8.0  1.4 8.8  1.9 0.01
P 0.001 0.01
Systolic blood pressure
(mmHg)
Baseline 137  13 137  14 NS
6 months 122  15 131  14 0.003
P 10
5 0.01
Diastolic blood pressure
(mmHg)
Baseline 73  97 5  12 NS
6 months 72  10 72  11 NS
P NS NS
LDL cholesterol concentration
(mg/dl)
Baseline 101  29 99  34 NS
6 months 91  28 93  30 NS
P NS NS
Weight (lbs)
Baseline 181.6  40.0 188.1  61.7† NS
6 months 181.5  40.2 188.7  58.8† NS
P NS NS
HAM-D scores*
Baseline 19  52 0  6N S
6 months 11  61 3  8N S
P 0.001 0.001
Pain scale
Baseline 6  26  2N S
6 months 4  34  3N S
P 0.001 0.01
Data are means  SD. *Depression score: 0–7, none; 8–13, mild; 14–18, moderate; 19–22, severe; 22,
very severe. †n  43 (one patient in wheelchair and weight not measured). NS, nonsigniﬁcant (P  0.05).
Table 3—QOL subscales and scores
Sertraline Placebo
Baseline 6 months Baseline 6 months
Subscales*
Diabetes control 69.6  13.4 49.8  22.0 66.7  18.6 55.7  17.7
Anxiety and worry 78.8  12.6 57.1  21.8 76.7  16.5 61.9  22.1
Social burden 68.2  17.3 43.8  25.8 63.7  25.2 50.4  23.8
Sexual function 67.8  28.2 56.7  31.2 66.6  32.4 61.1  33.2
Energy and mobility 67.6  16.2 44.6  21.1 63.1  20.1 49.7  22
Scores†
Overall QOL 3.5  3 50.0  3 3.0  2 4.0  2
Diabetes severity 6.0  3.0 5.0  2.0 6.0  3.0 5.0  2.0
*Data are means  SD. P  0.05 for all subscales for both groups except for sexual function in the placebo
group; no difference between groups. †Data are medians  interquartile range. Improvement is an increase
in overall QOL and a decrease in diabetes severity. P  0.05 for both scores but no difference between
groups.
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tients in a busy ofﬁce practice, espe-
cially if both questions were answered
in the afﬁrmative.
Becausedepressionissigniﬁcantlyas-
sociated with treatment nonadherence
(25), it is likely that the improvement in
A1C and systolic blood pressure levels in
both groups was due to better adherence
to the treatment recommendations of the
nurses.Oneinterpretationoftheseresults
is that increased contact with a sympa-
thetic questioner (and listener) helps pa-
tients with depression, leading to better
medication adherence, but pharmacolog-
ical treatment of the underlying depres-
sion still yields an incremental beneﬁt.
These results suggest an effective ap-
proach to the time constraints hindering
primary care physicians caring for pa-
tients with poor glycemic control in
whom depression is suspected, especially
in low-income, minority populations.
Whooley’s screening questionnaire could
be used liberally in those patients, and if
results were positive (especially if both
questions were answered in the afﬁrma-
tive), an antidepressant should be consid-
ered. These patients can be difﬁcult to treat
successfully, but, in this manner, both de-
pressionanduncontrolleddiabetesandsys-
tolic blood pressure may be improved.
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